Please note that following on from information provided to NICE by the company in July 2018, the appraisal of Lenalidomide for untreated follicular lymphoma [ID1245] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Decision | Selected |
| Process | TA |
| ID number | 1245 |
Project Team
| Project lead | Michelle Adhemar |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in July 2018, the appraisal of Lenalidomide for untreated follicular lymphoma [ID1245] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 01 August 2018 | Suspended. Company update |
| 01 August 2018 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of lenalidomide within its marketing authorisation for treating follicular, untreated lymphoma. Following a recent update from the company, NICE has decided to suspend this appraisal on its work programme. As the appraisal has been referred, NICE will continue to monitor any developments and will provide a further update in due course. |
| 08 June 2018 - 06 July 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 27 June 2018 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual